Focused On-demand Library for Folliculin

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

BHD skin lesion fibrofolliculoma protein; Birt-Hogg-Dube syndrome protein

Alternative UPACC:

Q8NFG4; A6NJJ8; Q6ZRX1; Q96BD2; Q96BE4


Folliculin, identified by its alternative names BHD skin lesion fibrofolliculoma protein and Birt-Hogg-Dube syndrome protein, is a multi-functional entity pivotal in amino acid availability response and glycolysis regulation. It acts as a GTPase-activating protein, influencing the mTORC1 signaling cascade and thereby controlling MiT/TFE factors TFEB and TFE3. Its role extends to regulating glycolysis by interacting with lactate dehydrogenase LDHA.

Therapeutic significance:

Folliculin's involvement in diseases such as Birt-Hogg-Dube syndrome, Primary spontaneous pneumothorax, and Renal cell carcinoma underscores its therapeutic potential. Understanding the role of Folliculin could open doors to potential therapeutic strategies, especially in targeting the diverse renal tumors and skin lesions associated with these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.